EAST MILLSTONE, N.J.--(BUSINESS WIRE)--Life Sciences Research, Inc. (NYSE Arca: LSR) announced today that it has amended its $70 million long term financing to reduce the principal amount to $60 million and the interest rate to LIBOR plus 350 basis points.
